{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:17:29Z","timestamp":1783570649424,"version":"3.55.0"},"reference-count":50,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.3724\/abbs.2026057","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:52:21Z","timestamp":1774605141000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Shikonin sensitises osimertinib-resistant lung                     adenocarcinoma to ferroptosis through HES1-mediated ATF3 upregulation"],"prefix":"10.3724","author":[{"given":"Haiwen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuetong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihe","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence                         and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74: 229-263.","journal-title":"CA Cancer J Clin"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"Hendriks LEL","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, Tan DSW. Non-small-cell lung cancer. Nat Rev Dis                             Primers, 2024, 10:","journal-title":"Nat Rev Dis                             Primers"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"Riely GJ","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A. Non-small cell lung cancer, version 4.2024. J Natl Compr                             Cancer Netw, 2024, 22: 249-274.","journal-title":"J Natl Compr                             Cancer Netw"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"Planchard D","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, Yang JCH, Yanagitani N, Kim SW, Sugawara S. Osimertinib with or without chemotherapy in EGFR-mutated                         advanced NSCLC. N Engl J Med, 2023, 389: 1935-1948.","journal-title":"N Engl J Med"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"Ramalingam SS","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C. Overall survival with osimertinib in untreated, EGFR-mutated                         advanced NSCLC. N Engl J Med, 2020, 382: 41-50.","journal-title":"N Engl J Med"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"Tsuboi M","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, Wang J. Overall survival with osimertinib in resected EGFR-mutated                         NSCLC. N Engl J Med, 2023, 389: 137-147.","journal-title":"N Engl J Med"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"Sequist LV","year":"2020","unstructured":"Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JCH. Osimertinib plus savolitinib in patients with EGFR                         mutation-positive, MET-amplified, non-small-cell lung cancer after                         progression on EGFR tyrosine kinase inhibitors: interim results from a                         multicentre, open-label, phase 1b study. Lancet Oncol, 2020, 21: 373-386.","journal-title":"Lancet Oncol"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"156139","DOI":"10.1016\/j.phymed.2024.156139","volume":"135","author":"Lu C","year":"2024","unstructured":"Lu C, Zhang Z, Fan Y, Wang X, Qian J, Bian Z. Shikonin induces ferroptosis in osteosarcomas through the                         mitochondrial ROS-regulated HIF-1\u03b1\/HO-1 axis. Phytomedicine, 2024, 135:","journal-title":"Phytomedicine"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/cancers14051114","volume":"14","author":"Markowitsch SD","year":"2022","unstructured":"Markowitsch SD, Vakhrusheva O, Schupp P, Akele Y, Kitanovic J, Slade KS, Efferth T. Shikonin inhibits cell growth of sunitinib-resistant renal cell                         carcinoma by activating the necrosome complex and inhibiting the AKT\/mTOR                         signaling pathway. Cancers, 2022, 14:","journal-title":"Cancers"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.7150\/ijbs.36955","volume":"16","author":"Zhang N","year":"2020","unstructured":"Zhang N, Peng F, Wang Y, Yang L, Wu F, Wang X, Ye C. Shikonin induces colorectal carcinoma cells apoptosis and                         autophagy by targeting galectin-1\/JNK signaling axis. Int J Biol Sci, 2020, 16: 147-161.","journal-title":"Int J Biol Sci"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.3390\/nu17193085","volume":"17","author":"Lew CY","year":"2025","unstructured":"Lew CY, Tang YT, Lee AYJ, Chin ZJ, Chang WL, Chen CH, Chye SM. Shikonin as a dietary phytochemical with multi-target anti-cancer                         activities: from molecular mechanisms to translational applications. Nutrients, 2025, 17:","journal-title":"Nutrients"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"117395","DOI":"10.1016\/j.biopha.2024.117395","volume":"179","author":"Yen JH","year":"2024","unstructured":"Yen JH, Keak PY, Wu CL, Chen HJ, Gao WY, Liou JW, Chen YR. Shikonin, a natural naphthoquinone phytochemical, exerts                         anti-leukemia effects in human CBF-AML cell lines and zebrafish xenograft                         models. Biomed                             Pharmacother, 2024, 179:","journal-title":"Biomed                             Pharmacother"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.3390\/ijms26062661","volume":"26","author":"Doddapaneni R","year":"2025","unstructured":"Doddapaneni R, Tucker JD, Lu PJ, Lu QL. Synergistic effect of ribitol and shikonin promotes apoptosis in                         breast cancer cells. Int J Mol Sci, 2025, 26:","journal-title":"Int J Mol Sci"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3390\/cancers13040882","volume":"13","author":"Markowitsch SD","year":"2021","unstructured":"Markowitsch SD, Juetter KM, Schupp P, Hauschulte K, Vakhrusheva O, Slade KS, Thomas A. Shikonin reduces growth of docetaxel-resistant prostate cancer                         cells mainly through necroptosis. Cancers, 2021, 13:","journal-title":"Cancers"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"154701","DOI":"10.1016\/j.phymed.2023.154701","volume":"112","author":"Ni M","year":"2023","unstructured":"Ni M, Zhou J, Zhu Z, Xu Q, Yin Z, Wang Y, Zheng Z. Shikonin and cisplatin synergistically overcome cisplatin                         resistance of ovarian cancer by inducing ferroptosis via upregulation of                         HMOX1 to promote Fe2+ accumulation. Phytomedicine, 2023, 112:","journal-title":"Phytomedicine"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"155214","DOI":"10.1016\/j.phymed.2023.155214","volume":"123","author":"Hu X","year":"2024","unstructured":"Hu X, Peng X, Zhang Y, Fan S, Liu X, Song Y, Ren S. Shikonin reverses cancer-associated fibroblast-induced                         gemcitabine resistance in pancreatic cancer cells by suppressing                         monocarboxylate transporter 4-mediated reverse Warburg effect. Phytomedicine, 2024, 123:","journal-title":"Phytomedicine"},{"key":"CITATION17","doi-asserted-by":"crossref","unstructured":"Wang L, Stadlbauer B, Lyu C, Buchner A, Pohla H. Shikonin                         enhances the antitumor effect of cabazitaxel in prostate cancer stem cells                         and reverses cabazitaxel resistance by inhibiting ABCG2 and ALDH3A1.                              Am J Cancer Res                          2020, 10:                         3784\u20133800.","DOI":"10.21203\/rs.3.rs-58823\/v1"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"103974","DOI":"10.1016\/j.xphs.2025.103974","volume":"114","author":"Deng H","year":"2025","unstructured":"Deng H, Zhang H, Zhao Y, Chen T, Mao X, Li J, Li M. Co-encapsulated with shikonin\/doxorubicin pH-sensitive liposomes:                         preparation, characterization and its synergistic effect in drug-resistant                         breast cancer cells. J Pharm Sci, 2025, 114:","journal-title":"J Pharm Sci"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"Stockwell BR","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological                         functions, and therapeutic applications. Cell, 2022, 185: 2401-2421.","journal-title":"Cell"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"19573","DOI":"10.1021\/acs.jmedchem.4c01908","volume":"67","author":"Xu G","year":"2024","unstructured":"Xu G, Liang Q, Gao L, Xu S, Luo W, Wu Q, Li J. Developing an arene binuclear ruthenium(II) complex to induce                         ferroptosis and activate the cGAS-STING pathway: targeted inhibiting growth                         and metastasis of triple negative breast cancer. J Med Chem, 2024, 67: 19573-19585.","journal-title":"J Med Chem"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cac2.12250","volume":"42","author":"Zhao L","year":"2022","unstructured":"Zhao L, Zhou X, Xie F, Zhang L, Yan H, Huang J, Zhang C. Ferroptosis in cancer and cancer immunotherapy. Cancer Commun, 2022, 42: 88-116.","journal-title":"Cancer Commun"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"Zhang C","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug                         resistance. Mol Cancer, 2022, 21:","journal-title":"Mol Cancer"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/cas.70113","volume":"116","author":"Men B","year":"2025","unstructured":"Men B, Chen Z, Ge H, Yang Z, Yun L, Jiang J, Dian M. Dauricine overcomes osimertinib resistance in lung cancer by                         inducing ferroptosis via stabilizing SAT1. Cancer Sci, 2025, 116: 2256-2269.","journal-title":"Cancer Sci"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s11658-021-00271-y","volume":"26","author":"Fu D","year":"2021","unstructured":"Fu D, Wang C, Yu L, Yu R. Induction of ferroptosis by ATF3 elevation alleviates cisplatin                         resistance in gastric cancer by restraining Nrf2\/Keap1\/xCT signaling. Cell Mol Biol                             Lett, 2021, 26:","journal-title":"Cell Mol Biol                             Lett"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.21037\/tlcr-21-303","volume":"10","author":"Zhang T","year":"2021","unstructured":"Zhang T, Sun B, Zhong C, Xu K, Wang Z, Hofman P, Nagano T. Targeting histone deacetylase enhances the therapeutic effect of                         erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma. Transl Lung Cancer                             Res, 2021, 10: 1857-1872.","journal-title":"Transl Lung Cancer                             Res"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00438-025-02259-1","volume":"300","author":"Magesh V","year":"2025","unstructured":"Magesh V, Sekar R, AlZahrani A, Balasubramanian R, Abdelsalam SA, Rajendran P. HES1 in cancer: a key player in tumorigenesis and its prognostic                         significance. Mol Genet                             Genomics, 2025, 300:","journal-title":"Mol Genet                             Genomics"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","volume":"3","author":"Chmielecki J","year":"2011","unstructured":"Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L. Optimization of dosing for EGFR-mutant non-small cell lung cancer                         with evolutionary cancer modeling. Sci Transl                             Med, 2011, 3:","journal-title":"Sci Transl                             Med"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12935-021-02056-x","volume":"21","author":"Xia L","year":"2021","unstructured":"Xia L, Yang F, Wu X, Li S, Kan C, Zheng H, Wang S. SHP2 inhibition enhances the anticancer effect of Osimertinib in                         EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated                         stemness. Cancer Cell Int, 2021, 21:","journal-title":"Cancer Cell Int"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"216062","DOI":"10.1016\/j.canlet.2023.216062","volume":"556","author":"Kleczko EK","year":"2023","unstructured":"Kleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM. Novel EGFR-mutant mouse models of lung adenocarcinoma reveal                         adaptive immunity requirement for durable osimertinib response. Cancer Lett, 2023, 556:","journal-title":"Cancer Lett"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/cas.15674","volume":"114","author":"Takahashi H","year":"2023","unstructured":"Takahashi H, Sakakibara\u2010Konishi J, Furuta M, Shoji T, Tsuji K, Morinaga D, Kikuchi E. Notch pathway regulates osimertinib drug-tolerant persistence in                          EGFR-mutated non-small-cell lung cancer. Cancer Sci, 2023, 114: 1635-1650.","journal-title":"Cancer Sci"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"110588","DOI":"10.1016\/j.cbi.2023.110588","volume":"382","author":"Qian X","year":"2023","unstructured":"Qian X, Zhu L, Xu M, Liu H, Yu X, Shao Q, Qin J. Shikonin suppresses small cell lung cancer growth via inducing                         ATF3-mediated ferroptosis to promote ROS accumulation. Chem-Biol                             Interact, 2023, 382:","journal-title":"Chem-Biol                             Interact"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","volume":"36","author":"Ramalingam SS","year":"2018","unstructured":"Ramalingam SS, Yang JCH, Lee CK, Kurata T, Kim DW, John T, Nogami N. Osimertinib as first-line treatment of EGFR                         mutation-positive advanced non\u2013small-cell lung cancer. J Clin Oncol, 2018, 36: 841-849.","journal-title":"J Clin Oncol"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"Fu K","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung                         cancer patients with osimertinib resistance. J Hematol Oncol, 2022, 15:","journal-title":"J Hematol Oncol"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"176871","DOI":"10.1016\/j.ejphar.2024.176871","volume":"980","author":"Chen L","year":"2024","unstructured":"Chen L, Chen WD, Xu YX, Ren YY, Zheng C, Lin YY, Zhou JL. Strategies for enhancing non-small cell lung cancer treatment:                         integrating Chinese herbal medicines with epidermal growth factor                         receptor-tyrosine kinase inhibitors therapy. Eur J                             Pharmacol, 2024, 980:","journal-title":"Eur J                             Pharmacol"},{"key":"CITATION35","unstructured":"Huang G, Liu X, Jiang T, Cao Y, Sang M, Song X, Zhou B, et                         al. Luteolin overcomes acquired resistance to osimertinib in                         non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway.                              Am J Cancer Res                          2023, 13:                         4145\u20134162."},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"105701","DOI":"10.1016\/j.phrs.2021.105701","volume":"170","author":"Cai X","year":"2021","unstructured":"Cai X, Miao J, Sun R, Wang S, Molina-Vila MA, Chaib I, Rosell R. Dihydroartemisinin overcomes the resistance to osimertinib in                         EGFR-mutant non-small-cell lung cancer. Pharmacol Res, 2021, 170:","journal-title":"Pharmacol Res"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"840889","DOI":"10.3389\/fphar.2022.840889","volume":"13","author":"Yao J","year":"2022","unstructured":"Yao J, Lu Y, Jiao L, Bi L, Yang W, Su L, Shi J. Chinese herbal medicine (Yiqi-Yangyin-Jiedu decoction) combined                         with osimertinib as First-Line treatment in EGFR mutation-positive advanced                         non-small-cell lung cancer (CATLA-2): a study protocol for a double-blind                         randomized controlled trial. Front Pharmacol, 2022, 13:","journal-title":"Front Pharmacol"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"153805","DOI":"10.1016\/j.phymed.2021.153805","volume":"94","author":"Sun Q","year":"2022","unstructured":"Sun Q, Gong T, Liu M, Ren S, Yang H, Zeng S, Zhao H. Shikonin, a naphthalene ingredient: therapeutic actions,                         pharmacokinetics, toxicology, clinical trials and pharmaceutical researches. Phytomedicine, 2022, 94:","journal-title":"Phytomedicine"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1038\/s41401-025-01605-8","volume":"46","author":"Xu X","year":"2025","unstructured":"Xu X, Kalambhe DR, Yu Y, Yu L, Gu Z, Jin X, Wang H. Co-delivery of shikonin and JQ1 inhibits triple-negative breast                         tumor progression and lung metastasis through inhibition of                         epithelial-mesenchymal transition and vasculogenic mimicry. Acta Pharmacol                             Sin, 2025, 46: 3314-3326.","journal-title":"Acta Pharmacol                             Sin"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41418-023-01239-5","volume":"31","author":"Wang Z","year":"2024","unstructured":"Wang Z, Shen N, Wang Z, Yu L, Yang S, Wang Y, Liu Y. TRIM3 facilitates ferroptosis in non-small cell lung cancer                         through promoting SLC7A11\/xCT K11-linked ubiquitination and degradation. Cell Death                             Differ, 2024, 31: 53-64.","journal-title":"Cell Death                             Differ"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"216465","DOI":"10.1016\/j.canlet.2023.216465","volume":"579","author":"Cai S","year":"2023","unstructured":"Cai S, Zhang B, Huang C, Deng Y, Wang C, Yang Y, Xiang Z. CTRP6 protects against ferroptosis to drive lung cancer                         progression and metastasis by destabilizing SOCS2 and augmenting the                         xCT\/GPX4 pathway. Cancer Lett, 2023, 579:","journal-title":"Cancer Lett"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"e2204133","DOI":"10.1002\/smll.202204133","volume":"19","author":"Wang L","year":"2023","unstructured":"Wang L, Fu H, Song L, Wu Z, Yu J, Guo Q, Chen C. Overcoming AZD9291 resistance and metastasis of NSCLC via                         ferroptosis and multitarget interference by nanocatalytic sensitizer plus                         AHP-DRI-12. Small, 2023, 19:","journal-title":"Small"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/15384047.2015.1016662","volume":"16","author":"Liu ZH","year":"2015","unstructured":"Liu ZH, Dai XM, Du B. Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol                             Ther, 2015, 16: 353-359.","journal-title":"Cancer Biol                             Ther"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/ijc.31737","volume":"143","author":"Yuan Q","year":"2018","unstructured":"Yuan Q, Chen X, Han Y, Lei T, Wu Q, Yu X, Wang L. Modification of \u03b12,6-sialylation mediates the invasiveness and                         tumorigenicity of non-small cell lung cancer cells in vitro                         and in vivo via Notch1\/Hes1\/MMPs pathway. Intl J Cancer, 2018, 143: 2319-2330.","journal-title":"Intl J Cancer"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1172\/JCI126896","volume":"130","author":"Bousquet Mur E","year":"2020","unstructured":"Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I. Notch inhibition overcomes resistance to tyrosine kinase                         inhibitors in EGFR-driven lung adenocarcinoma. J Clin Invest, 2020, 130: 612-624.","journal-title":"J Clin Invest"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.7150\/jca.19142","volume":"8","author":"Sun L","year":"2017","unstructured":"Sun L, Ke J, He Z, Chen Z, Huang Q, Ai W, Wang G. HES1 promotes colorectal cancer cell resistance To 5-Fu by                         inducing Of EMT and ABC transporter proteins. J Cancer, 2017, 8: 2802-2808.","journal-title":"J Cancer"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41467-023-38833-7","volume":"14","author":"Zhang B","year":"2023","unstructured":"Zhang B, Dong S, Wang J, Huang T, Zhao P, Xu J, Liu D. NOTCH4\u0394L12_16 sensitizes lung adenocarcinomas to EGFR-TKIs                         through transcriptional down-regulation of HES1. Nat Commun, 2023, 14:","journal-title":"Nat Commun"},{"key":"CITATION48","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3724\/abbs.2025042","volume":"57","author":"Cui M","year":"2025","unstructured":"Cui M, Ding X, Jiang Y, Zhang L, Cao W, Wang Y, Sheng Z. PDGFC secreted by cancer-associated fibroblasts promotes                         epithelial-mesenchymal transition and immunosuppression in lung                         adenocarcinoma. Acta Biochim Biophys                             Sin, 2025, 57: 1625-1635.","journal-title":"Acta Biochim Biophys                             Sin"},{"key":"CITATION49","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41418-019-0380-z","volume":"27","author":"Wang L","year":"2020","unstructured":"Wang L, Liu Y, Du T, Yang H, Lei L, Guo M, Ding HF. ATF3 promotes erastin-induced ferroptosis by suppressing system                         Xc. Cell Death                             Differ, 2020, 27: 662-675.","journal-title":"Cell Death                             Differ"},{"key":"CITATION50","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/s41401-021-00700-w","volume":"42","author":"Lu S","year":"2021","unstructured":"Lu S, Wang X, He C, Wang L, Liang S, Wang C, Li C. ATF3 contributes to brucine-triggered glioma cell ferroptosis via                         promotion of hydrogen peroxide and iron. Acta Pharmacol                             Sin, 2021, 42: 1690-1702.","journal-title":"Acta Pharmacol                             Sin"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/8BDB33A14520408986FA2C667700A4C4","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026057","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/8BDB33A14520408986FA2C667700A4C4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:00:44Z","timestamp":1783569644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":50,"URL":"https:\/\/doi.org\/10.3724\/abbs.2026057","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}